Which venous duplex ultrasound CPT code should be ordered for a patient with possible left lower‑extremity deep vein thrombosis, and what is the risk of recurrence while the patient is on therapeutic warfarin and low‑dose aspirin for a prior clot?

Ultrasound Ordering and DVT Recurrence Risk on Anticoagulation

CPT Code for Left Leg DVT Evaluation

Order CPT code 93970 (duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study) or CPT 93971 (unilateral or limited study). 1

• For a patient with unilateral left leg symptoms, a complete duplex ultrasound from the inguinal ligament to the ankle is the definitive diagnostic test, including evaluation of the common femoral, superficial femoral, popliteal, posterior tibial, and peroneal veins. 2, 1
• The American College of Chest Physicians recommends proceeding directly to ultrasound without D-dimer testing when clinical suspicion is high (such as a patient with prior DVT history now presenting with new leg symptoms). 1
• While some practitioners perform unilateral studies only, bilateral scanning may identify asymptomatic contralateral DVT in 5-13% of cases, particularly in inpatients or high-risk patients. 3, 4

Risk of Recurrent DVT While on Warfarin and Aspirin

The risk of recurrent VTE while on therapeutic warfarin is approximately 1-2% per year, but breakthrough thrombosis can occur if anticoagulation is subtherapeutic or if the patient has developed warfarin resistance. 5, 6

Key Factors Affecting Recurrence Risk:

• Therapeutic INR range (2.0-3.0) is critical: The FDA label specifies that warfarin should maintain an INR of 2.0-3.0 for DVT treatment, and an INR >4.0 provides no additional benefit while increasing bleeding risk. 6
• Time in therapeutic range matters significantly: Studies show patients in usual care are only in therapeutic range 33-64% of the time, whereas anticoagulation clinic management achieves 56-93% time in range. 6
• Adding aspirin to warfarin does not provide additional VTE protection: The American Society of Hematology 2020 guidelines found that anticoagulation is significantly more effective than aspirin for secondary VTE prevention (aspirin increased nonfatal PE risk by RR 3.10 and DVT risk by RR 3.15 compared to standard anticoagulation). 5

Immediate Actions Required:

• Check her most recent INR immediately: If INR is subtherapeutic (<2.0), this explains potential breakthrough thrombosis and requires dose adjustment. 6
• Verify medication adherence: Warfarin's anticoagulant effect persists beyond 24 hours, but missed doses or drug interactions can cause subtherapeutic levels. 6
• Review interacting medications: Many drugs alter warfarin metabolism; any new medications, discontinued drugs, or irregular intake necessitates additional INR monitoring. 6

Clinical Pitfall to Avoid:

• Do not assume adequate anticoagulation based on prescription alone: Even compliant patients on warfarin can have subtherapeutic INR due to dietary vitamin K intake, drug interactions, or genetic variations in CYP2C9 and VKORC1 enzymes. 6
• The combination of warfarin plus aspirin increases bleeding risk without improving VTE prevention: Unless she has a specific cardiac indication (e.g., mechanical heart valve, recent MI), the aspirin may be unnecessary and should be reconsidered. 5, 6

Likelihood Assessment:

• If her INR has been consistently therapeutic (2.0-3.0), the annual risk of recurrent VTE on warfarin is 1-2%, making breakthrough thrombosis uncommon but possible. 5
• If her INR is subtherapeutic or she has missed doses, the risk increases substantially, approaching that of an untreated patient (approximately 10-15% over 3 months). 5
• Approximately 15% of untreated symptomatic distal DVTs extend into proximal veins, emphasizing the importance of prompt diagnosis and ensuring therapeutic anticoagulation. 1